Disclaimer
This website is provided for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction where such distribution, publication availability or use would be contrary to applicable law or regulation or would require any registration or licensing within placement or subscription or solicitation, under the United States Securities Act of 1993 as amended, or any other US state securities laws, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever in any jurisdiction, including the United States.
By clicking “ACCEPT” below, you confirm your agreement to the above, and, in particular, you confirm that you qualify as a Professional Client or Eligible Counterparty under the FCA rules. Please also refer to the Terms and Conditions section on the website.
What we learnt at the clinic…
February 2017
Tragically, the lives of most of us have been touched by cancer and the battle to treat cancer has been ongoing for many years with varying degrees of success. The ubiquity of this disease led us to a Swedish organisation, Elekta. For the last twenty years this company has been the pre‑eminent designer and producer of linear accelerators (LINACs), the machines that are used to administer radiotherapy. The company’s commitment to R&D was impressive, and implied that it was always going to be a major player in what is, sadly, a growth industry. Whilst this excited us we were never able to get comfortable with their accounting policies and this deterred us from making an investment.
Related Posts
© 2025 S. W. Mitchell Capital LLP. All Rights Reserved. S. W. Mitchell Capital LLP is authorised and regulated by the Financial Conduct Authority. S. W. Mitchell Capital LLP is a Limited Liability Partnership registered in England no. OC312953
Registered address Princes House, 38 Jermyn Street, London, SW1Y 6DN